Definium Therapeutics reports second positive Phase 3 trial of LSD candidate DT120 for generalised anxiety disorder

Definium Therapeutics reported positive topline results from Panorama, its second Phase 3 study of the LSD-derived candidate DT120 in generalised anxiety disorder, and the company’s third positive Phase 3 readout since June. The trial randomised 245 participants at approximately 32 US and international sites to a single 100 µg dose of DT120, a 50 µg dose, or placebo, followed by a 12-week double-blind period and a 40-week extension. The supplied material identifies the study design and the positive topline outcome, but does not provide the numerical efficacy results, statistical significance, safety findings, or details of the extension outcomes. Those missing data limit assessment of the treatment effect and clinical implications.